» Articles » PMID: 36589462

QInward Variability-based Proarrhythmic Risk Assessment of Drugs Using Deep Learning Model

Overview
Journal Front Physiol
Date 2023 Jan 2
PMID 36589462
Authors
Affiliations
Soon will be listed here.
Abstract

Many researchers have suggested evaluation methods and Torsades de Pointes (TdP) metrics to assess the proarrhythmic risk of a drug based on the simulation, as part of the Comprehensive Proarrhythmia Assay (CiPA) project. In the previous study, we validated the robustness of 12 features using the ordinal logistic regression (OLR) model by comparing the classification performances of metrics according to the experimental datasets used; however, the OLR model using 12 features did not provide desirable results. This study proposed a convolutional neural network (CNN) model using the variability of promising TdP metrics hypothesizing that the variability of features based on beats has more information than the single value of features. We performed the action potential (AP) simulation using a human ventricular myocyte model to calculate seven features representing the electrophysiological cell states of drug effects over 1,000 beats: qNet, qInward, intracellular calcium duration at returning to 50% baseline (CaD50) and 90% baseline (CaD90), AP duration at 50% repolarization (APD50) and 90% repolarization (APD90), and dVm/dtMax_repol. The proposed CNN classifier was trained using 12 train drugs and tested using 16 test drugs among CiPA drugs. The torsadogenic risk of drugs was classified as high, intermediate, and low risks. We determined the CNN classifier by comparing the classification performance according to the variabilities of seven biomarkers computed from the drug simulation using the Chantest dataset. The proposed CNN classifier performed the best when using qInward variability to classify the TdP-risk drugs with 0.94 AUC for high risk and 0.93 AUC for low risk. In addition, the final CNN classifier was validated using the qInward variability obtained after merging three datasets, but the model performance decreased to a moderate level of 0.75 and 0.78 AUC. These results suggest the need for the proposed CNN model to be trained and tested using various types of drugs.

Citing Articles

Machine learning approach to evaluate TdP risk of drugs using cardiac electrophysiological model including inter-individual variability.

Fuadah Y, Qauli A, Marcellinus A, Pramudito M, Lim K Front Physiol. 2023; 14:1266084.

PMID: 37860622 PMC: 10584148. DOI: 10.3389/fphys.2023.1266084.

References
1.
Li Z, Dutta S, Sheng J, Tran P, Wu W, Chang K . Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology. Circ Arrhythm Electrophysiol. 2017; 10(2):e004628. DOI: 10.1161/CIRCEP.116.004628. View

2.
Sager P, Gintant G, Rick Turner J, Pettit S, Stockbridge N . Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014; 167(3):292-300. DOI: 10.1016/j.ahj.2013.11.004. View

3.
Jeong D, Danadibrata R, Marcellinus A, Lim K . Validation of biomarkers for drug screening through ordinal logistic regression. Front Physiol. 2022; 13:1009647. PMC: 9583152. DOI: 10.3389/fphys.2022.1009647. View

4.
. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist. 2005; 70(202):61133-4. View

5.
Onakpoya I, Heneghan C, Aronson J . Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016; 14:10. PMC: 4740994. DOI: 10.1186/s12916-016-0553-2. View